Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Ziller V Schüssel K Czeche S Franzmann A Klöckner D Quinzler R Schulz M Möhrke W Hadji P

36^th European Symposium on Calcified Tissues, 23. - 27.05.2009, Vienna, Austria.

ECTS 2009, Wien; Poster: Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Bone 2009; 44 (Suppl. 2): S449 (Abstract P511)

Conflicts of interests: W.Moehrke, Procter and Gamble Pharmaceuticals, Employee; M.Schulz, Procter and Gamble Pharmaceuticals, Grant; P.Hadji, Procter and Gamble Pharmaceuticals, Consultant.

Impact of rebate contract legislation on generic substitution of valproate – a retrospective study of ambulatory drug dispensing in the DAPI database

Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib

Effect of generic switch on pharmacy refill compliance after ramipril patent expiry – a retrospective study using the DAPI database

Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.

Comparison of different ways of calculation (DDD vs. SPC) to determine persistence and compliance with beta blockers in the DAPI database.

Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.

Association between generic substitution of valproate and therapeutic modification of antiepileptic therapy – a cohort study with time-dependent exposure utilizing the DAPI ambulatory drug claims data